https://novapharmanews.com/us/news/fda-easing-restrictions-unproven-peptides 2026-06-01T06:31:53.920Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z FDA Considers Easing Restrictions on Unproven Peptides https://novapharmanews.com/uploads/articles/fda-easing-restrictions-unproven-peptides.webp FDA Considers Easing Restrictions on Unproven Peptides https://novapharmanews.com/us/news/sunlight-glp-1-2026-fda-decision-compounded-semaglutide 2026-06-01T06:31:53.635Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z Sunlight GLP-1 2026: FDA's Decision on Compounded Semaglutide semaglutide, GLP-1 https://novapharmanews.com/uploads/articles/sunlight-glp-1-2026-fda-decision-compounded-semaglutide.webp Sunlight GLP-1 2026: FDA's Decision on Compounded Semaglutide https://novapharmanews.com/us/news/fda-approvals-oncology-jan-mar-2026 2026-06-01T06:32:52.175Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z FDA Approvals in Oncology: January-March 2026 oncology https://novapharmanews.com/uploads/articles/fda-approvals-oncology-jan-mar-2026.webp FDA Approvals in Oncology: January-March 2026 https://novapharmanews.com/us/news/bayer-acquisition-eye-drug-biotech 2026-06-01T06:28:51.342Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z Bayer's $300M Acquisition: A Strategic Move in Ophthalmology https://novapharmanews.com/uploads/articles/bayer-acquisition-eye-drug-biotech.webp Bayer's $300M Acquisition: A Strategic Move in Ophthalmology https://novapharmanews.com/us/news/2025-drug-approvals-biopharma-resilience 2026-06-01T06:31:53.852Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z 2025 Drug Approvals: Biopharma's Resilience Amidst Challenges https://novapharmanews.com/uploads/articles/2025-drug-approvals-biopharma-resilience.webp 2025 Drug Approvals: Biopharma's Resilience Amidst Challenges https://novapharmanews.com/us/news/us-fda-proposes-regulations-weight-loss-drug-compounding 2026-06-01T06:30:49.796Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z US FDA Proposes New Regulations on Weight-Loss Drug Compounding semaglutide, liraglutide, weight loss https://novapharmanews.com/uploads/articles/us-fda-proposes-regulations-weight-loss-drug-compounding.webp US FDA Proposes New Regulations on Weight-Loss Drug Compounding https://novapharmanews.com/us/news/fda-flashback-breast-cancer-april-2026 2026-06-01T06:30:50.935Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z FDA Flashback: Key Breast Cancer Decisions from April 2026 oncology, breast cancer https://novapharmanews.com/uploads/articles/fda-flashback-breast-cancer-april-2026.webp FDA Flashback: Key Breast Cancer Decisions from April 2026 https://novapharmanews.com/us/news/fda-eases-restrictions-peptides-drug-approvals 2026-06-01T06:30:51.455Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z FDA Eases Restrictions on Peptides: Implications for Drug Approvals https://novapharmanews.com/uploads/articles/fda-eases-restrictions-peptides-drug-approvals.webp FDA Eases Restrictions on Peptides: Implications for Drug Approvals https://novapharmanews.com/us/news/top-10-takeover-targets-2026 2026-06-01T06:31:54.086Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z Top 10 Takeover Targets of 2026: Market Analysis https://novapharmanews.com/uploads/articles/top-10-takeover-targets-2026.webp Top 10 Takeover Targets of 2026: Market Analysis https://novapharmanews.com/us/news/fda-permanent-ban-compounded-glp-1s 2026-06-01T06:32:52.892Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z FDA's Permanent Ban on Compounded GLP-1s: What It Means for Pharma GLP-1 https://novapharmanews.com/uploads/articles/fda-permanent-ban-compounded-glp-1s.webp FDA's Permanent Ban on Compounded GLP-1s: What It Means for Pharma https://novapharmanews.com/us/news/eli-lilly-acquires-centessa-pharmaceuticals-market-analysis 2026-06-01T06:37:18.873Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z Eli Lilly Acquires Centessa Pharmaceuticals: Market Analysis https://novapharmanews.com/uploads/articles/eli-lilly-acquires-centessa-pharmaceuticals-market-analysis.webp Eli Lilly Acquires Centessa Pharmaceuticals: Market Analysis https://novapharmanews.com/us/news/top-biotech-gainers-codx-nrxp-nvax-clinical-trials-update 2026-06-01T06:44:27.421Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z Top Biotech Gainers: CODX, NRXP, NVAX - Clinical Trials Update CODX, NRXP, NVAX, Ebola https://novapharmanews.com/uploads/articles/top-biotech-gainers-codx-nrxp-nvax-clinical-trials-update.webp Top Biotech Gainers: CODX, NRXP, NVAX - Clinical Trials Update https://novapharmanews.com/us/news/ophthalmology-pipeline-milestones-q2-2026 2026-06-01T06:30:51.362Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z Ophthalmology Pipeline Milestones for Q2 2026: What to Expect https://novapharmanews.com/uploads/articles/ophthalmology-pipeline-milestones-q2-2026.webp Ophthalmology Pipeline Milestones for Q2 2026: What to Expect https://novapharmanews.com/us/news/fda-peptides-bulk-drug-compounding 2026-06-01T06:22:20.933Z NovaPharmaNews en-US 2026-06-01T06:15:59.933Z FDA Considers Adding Peptides to Bulk Drug Compounding List https://novapharmanews.com/uploads/articles/fda-peptides-bulk-drug-compounding.webp FDA Considers Adding Peptides to Bulk Drug Compounding List https://novapharmanews.com/apac/news/early-access-disparities-innovative-therapies 2026-06-01T06:23:09.166Z NovaPharmaNews en-AU 2026-06-01T06:15:53.438Z Disparities in Early Access to Innovative Therapies: A Global Overview https://novapharmanews.com/uploads/articles/early-access-disparities-innovative-therapies.webp Disparities in Early Access to Innovative Therapies: A Global Overview https://novapharmanews.com/apac/news/decade-ai-medical-device-regulation-2015-2025 2026-06-01T06:23:30.919Z NovaPharmaNews en-AU 2026-06-01T06:15:53.438Z A Decade of AI Medical Device Regulation: Key Updates https://novapharmanews.com/uploads/articles/decade-ai-medical-device-regulation-2015-2025.webp A Decade of AI Medical Device Regulation: Key Updates https://novapharmanews.com/us/news/pharma-in-focus-regulatory-updates 2026-06-01T06:22:08.749Z NovaPharmaNews en-US 2026-06-01T06:15:53.438Z Pharma in Focus: Regulatory Updates You Need to Know https://novapharmanews.com/uploads/articles/pharma-in-focus-regulatory-updates.webp Pharma in Focus: Regulatory Updates You Need to Know https://novapharmanews.com/us/news/fsma-final-rule-traceability-requirements 2026-06-01T06:22:25.818Z NovaPharmaNews en-US 2026-06-01T06:15:53.438Z FSMA Final Rule: New Traceability Requirements Impacting Food Safety https://novapharmanews.com/uploads/articles/fsma-final-rule-traceability-requirements.webp FSMA Final Rule: New Traceability Requirements Impacting Food Safety https://novapharmanews.com/eu/news/bio-pharma-outlook-2026-regulatory-updates 2026-06-01T06:23:26.572Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z Bio/Pharma Outlook 2026: Regulatory Updates and Implications https://novapharmanews.com/uploads/articles/bio-pharma-outlook-2026-regulatory-updates.webp Bio/Pharma Outlook 2026: Regulatory Updates and Implications https://novapharmanews.com/eu/news/international-school-clinical-oncology-annual-congress-2026 2026-06-01T06:23:02.114Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z International School of Clinical Oncology Annual Congress 2026: Key Insights oncology https://novapharmanews.com/uploads/articles/international-school-clinical-oncology-annual-congress-2026.webp International School of Clinical Oncology Annual Congress 2026: Key Insights https://novapharmanews.com/eu/news/horizon-scanning-ema-regulatory-updates 2026-06-01T06:23:22.080Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z Horizon Scanning at EMA: Regulatory Updates for Future Medicines https://novapharmanews.com/uploads/articles/horizon-scanning-ema-regulatory-updates.webp Horizon Scanning at EMA: Regulatory Updates for Future Medicines https://novapharmanews.com/eu/news/fda-delays-astrazeneca-breast-cancer-drug-review 2026-06-01T06:32:34.803Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights breast cancer https://novapharmanews.com/uploads/articles/fda-delays-astrazeneca-breast-cancer-drug-review.webp FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights https://novapharmanews.com/eu/news/2026-italy-drug-medical-device-litigation-report 2026-06-01T06:32:07.926Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z 2026 Italy Drug & Medical Device Litigation Report: Key Insights https://novapharmanews.com/uploads/articles/2026-italy-drug-medical-device-litigation-report.webp 2026 Italy Drug & Medical Device Litigation Report: Key Insights https://novapharmanews.com/eu/news/rethinking-qa-qc-future-bio-pharmaceutical-analysis-2026 2026-06-01T06:23:08.761Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z Rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026 https://novapharmanews.com/uploads/articles/rethinking-qa-qc-future-bio-pharmaceutical-analysis-2026.webp Rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026 https://novapharmanews.com/eu/news/ascentage-pharma-eha-2026-clinical-advances 2026-06-01T06:23:31.682Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z Ascentage Pharma's 17 Clinical Advances at EHA 2026 https://novapharmanews.com/uploads/articles/ascentage-pharma-eha-2026-clinical-advances.webp Ascentage Pharma's 17 Clinical Advances at EHA 2026 https://novapharmanews.com/eu/news/us-europe-biosimilar-approvals-2026 2026-06-01T06:23:06.430Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z Biosimilar Approvals: U.S. vs. Europe Insights https://novapharmanews.com/uploads/articles/us-europe-biosimilar-approvals-2026.webp Biosimilar Approvals: U.S. vs. Europe Insights https://novapharmanews.com/eu/news/datroway-priority-review-metastatic-tnbc 2026-06-01T06:23:17.843Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z Datroway Receives Priority Review for Metastatic Triple-Negative Breast Cancer Datroway, oncology, breast cancer, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-priority-review-metastatic-tnbc.webp Datroway Receives Priority Review for Metastatic Triple-Negative Breast Cancer https://novapharmanews.com/eu/news/who-europe-access-novel-medicines 2026-06-01T06:23:12.845Z NovaPharmaNews en-GB 2026-06-01T06:15:53.438Z WHO/Europe's Initiative on Access to Novel Medicines https://novapharmanews.com/uploads/articles/who-europe-access-novel-medicines.webp WHO/Europe's Initiative on Access to Novel Medicines https://novapharmanews.com/apac/news/pharmaceuticals-market-size-share-analysis-2034 2026-06-01T06:32:05.075Z NovaPharmaNews en-AU 2026-06-01T06:15:53.438Z Pharmaceuticals Market Size and Share Analysis for 2034 https://novapharmanews.com/uploads/articles/pharmaceuticals-market-size-share-analysis-2034.webp Pharmaceuticals Market Size and Share Analysis for 2034 https://novapharmanews.com/apac/news/beone-medicines-phase-3-herizon-gea-data-nejm 2026-06-01T06:23:21.170Z NovaPharmaNews en-AU 2026-06-01T06:15:53.438Z BeOne Medicines Phase 3 HERIZON-GEA Data Published in NEJM oncology https://novapharmanews.com/uploads/articles/beone-medicines-phase-3-herizon-gea-data-nejm.webp BeOne Medicines Phase 3 HERIZON-GEA Data Published in NEJM https://novapharmanews.com/us/news/healthcare-dealmaker-megamergers-2026 2026-06-01T06:28:51.251Z NovaPharmaNews en-US 2026-06-01T06:15:53.438Z Healthcare Dealmakers Target Megamergers in 2026 https://novapharmanews.com/uploads/articles/healthcare-dealmaker-megamergers-2026.webp Healthcare Dealmakers Target Megamergers in 2026 https://novapharmanews.com/us/news/fda-guidance-next-gen-sequencing-gene-therapy-safety 2026-06-01T06:22:13.466Z NovaPharmaNews en-US 2026-06-01T06:15:53.438Z FDA Guidance on Next-Gen Sequencing for Gene Therapy Safety gene therapy https://novapharmanews.com/uploads/articles/fda-guidance-next-gen-sequencing-gene-therapy-safety.webp FDA Guidance on Next-Gen Sequencing for Gene Therapy Safety https://novapharmanews.com/apac/news/akeso-lung-cancer-drug-outperforms-immunotherapy 2026-06-01T06:23:16.898Z NovaPharmaNews en-AU 2026-06-01T06:15:53.438Z Akeso Lung Cancer Drug Outperforms Immunotherapy in China Trial oncology, lung cancer https://novapharmanews.com/uploads/articles/akeso-lung-cancer-drug-outperforms-immunotherapy.webp Akeso Lung Cancer Drug Outperforms Immunotherapy in China Trial https://novapharmanews.com/apac/news/newron-pharmaceuticals-june-investor-conferences 2026-06-01T06:23:11.616Z NovaPharmaNews en-AU 2026-06-01T06:15:53.438Z Newron Pharmaceuticals to Participate in June Investor Conferences https://novapharmanews.com/uploads/articles/newron-pharmaceuticals-june-investor-conferences.webp Newron Pharmaceuticals to Participate in June Investor Conferences https://novapharmanews.com/us/news/china-drug-development-oncology-us 2026-06-01T05:44:36.434Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z China’s Rise in Drug Development Looms Over U.S. Oncology Market oncology https://novapharmanews.com/uploads/articles/china-drug-development-oncology-us.webp China’s Rise in Drug Development Looms Over U.S. Oncology Market https://novapharmanews.com/us/news/vir-astellas-240m-prostate-cancer-trials 2026-06-01T05:43:02.864Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Vir-Astellas Secures $240M for Prostate Cancer Trials prostate cancer https://novapharmanews.com/uploads/articles/vir-astellas-240m-prostate-cancer-trials.webp Vir-Astellas Secures $240M for Prostate Cancer Trials https://novapharmanews.com/us/news/global-ma-trends-health-industries-2026-outlook 2026-06-01T05:42:57.971Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Global M&A Trends in Health Industries: 2026 Outlook https://novapharmanews.com/uploads/articles/global-ma-trends-health-industries-2026-outlook.webp Global M&A Trends in Health Industries: 2026 Outlook https://novapharmanews.com/us/news/altrx-glp-1-review-2026-fda-updates-semaglutide 2026-06-01T05:43:49.032Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z altRx GLP-1 Review 2026: FDA Updates on Semaglutide semaglutide, GLP-1 https://novapharmanews.com/uploads/articles/altrx-glp-1-review-2026-fda-updates-semaglutide.webp altRx GLP-1 Review 2026: FDA Updates on Semaglutide https://novapharmanews.com/us/news/fda-decisions-q2-2026-drug-approvals 2026-06-01T02:10:05.446Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z 5 FDA Drug Approvals to Watch in 2026 https://novapharmanews.com/uploads/articles/fda-drug-approvals-2026.webp 5 FDA Drug Approvals to Watch in 2026 https://novapharmanews.com/us/news/longeveron-q1-2026-financial-results-business-update 2026-06-01T05:44:14.516Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Longeveron Reports Q1 2026 Financial Results and Business Update https://novapharmanews.com/uploads/articles/longeveron-q1-2026-financial-results-business-update.webp Longeveron Reports Q1 2026 Financial Results and Business Update https://novapharmanews.com/us/news/chinese-pharma-innovators-global-expansion 2026-06-01T05:44:15.060Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Chinese Pharma Innovators Expand Globally with Innovative Deal Structures https://novapharmanews.com/uploads/articles/chinese-pharma-innovators-global-expansion.webp Chinese Pharma Innovators Expand Globally with Innovative Deal Structures https://novapharmanews.com/us/news/resilience-reinvention-biotech-maturity 2026-06-01T05:44:32.201Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Resilience and Reinvention: Biotech’s Year of Maturity https://novapharmanews.com/uploads/articles/resilience-reinvention-biotech-maturity.webp Resilience and Reinvention: Biotech’s Year of Maturity https://novapharmanews.com/us/news/china-approves-hernexeos-lung-cancer-treatment 2026-06-01T06:29:50.327Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z China Approves HERNEXEOS for Lung Cancer Treatment HERNEXEOS, oncology, lung cancer https://novapharmanews.com/uploads/articles/china-approves-hernexeos-lung-cancer-treatment.webp China Approves HERNEXEOS for Lung Cancer Treatment https://novapharmanews.com/us/news/pennsylvania-compounding-pharmacy-fda-warning-letter 2026-06-01T05:44:01.621Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Pennsylvania Compounding Pharmacy Receives FDA Warning Letter https://novapharmanews.com/uploads/articles/pennsylvania-compounding-pharmacy-fda-warning-letter.webp Pennsylvania Compounding Pharmacy Receives FDA Warning Letter https://novapharmanews.com/us/news/jpm26-biotech-ma-insights-market-analysis 2026-06-01T05:43:19.945Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z JPM26: Biotech M&A Insights and Market Analysis https://novapharmanews.com/uploads/articles/jpm26-biotech-ma-insights-market-analysis.webp JPM26: Biotech M&A Insights and Market Analysis https://novapharmanews.com/us/news/wockhardt-us-fda-approval-zaynich 2026-05-31T19:00:59.475Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Wockhardt Secures US FDA Approval for ZAYNICH: A Milestone for Indian Pharma ZAYNICH https://novapharmanews.com/uploads/articles/wockhardt-us-fda-approval-zaynich.webp Wockhardt Secures US FDA Approval for ZAYNICH: A Milestone for Indian Pharma https://novapharmanews.com/eu/news/privosegtor-ema-prime-optic-neuritis 2026-06-01T05:44:38.001Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Privosegtor Secures EMA PRIME Designation for Optic Neuritis optic neuritis https://novapharmanews.com/uploads/articles/privosegtor-ema-prime-optic-neuritis.webp Privosegtor Secures EMA PRIME Designation for Optic Neuritis https://novapharmanews.com/us/news/lilly-38b-investment-infectious-disease-portfolio 2026-06-01T06:30:50.190Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z Eli Lilly's $3.8B Investment in Infectious Disease Portfolio infectious diseases https://novapharmanews.com/uploads/articles/lilly-38b-investment-infectious-disease-portfolio.webp Eli Lilly's $3.8B Investment in Infectious Disease Portfolio https://novapharmanews.com/us/news/fda-blueprint-regulatory-risk-animal-testing-alternatives 2026-05-31T08:02:53.289Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z FDA Blueprint to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/uploads/articles/fda-blueprint-regulatory-risk-animal-testing-alternatives.webp FDA Blueprint to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/us/news/fda-new-guidance-ai-regulatory-restraint 2026-06-01T06:33:56.315Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z FDA's New Guidance on AI: Regulatory Restraint Explained https://novapharmanews.com/uploads/articles/fda-new-guidance-ai-regulatory-restraint.webp FDA's New Guidance on AI: Regulatory Restraint Explained https://novapharmanews.com/us/news/fda-device-guidance-agenda-2026 2026-06-01T06:30:50.420Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z FDA Device Guidance Agenda: Key Regulatory Updates for 2026 https://novapharmanews.com/uploads/articles/fda-device-guidance-agenda-2026.webp FDA Device Guidance Agenda: Key Regulatory Updates for 2026 https://novapharmanews.com/eu/news/25-posts-not-to-miss-elcc-2026-oncology 2026-06-01T05:44:33.225Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z 25 Posts Not To Miss From ELCC 2026: Oncology Insights oncology https://novapharmanews.com/uploads/articles/25-posts-not-to-miss-elcc-2026-oncology.webp 25 Posts Not To Miss From ELCC 2026: Oncology Insights https://novapharmanews.com/apac/news/biomarkers-digital-technologies-oncology-asia-2026 2026-06-01T05:43:00.479Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Biomarkers and Digital Technologies Transforming Oncology in Asia oncology https://novapharmanews.com/uploads/articles/biomarkers-digital-technologies-oncology-asia-2026.webp Biomarkers and Digital Technologies Transforming Oncology in Asia https://novapharmanews.com/apac/news/innovative-oncology-pharma-china 2026-06-01T05:43:06.742Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Innovative Oncology Pharma Companies in China: A Look Ahead oncology https://novapharmanews.com/uploads/articles/innovative-oncology-pharma-china.webp Innovative Oncology Pharma Companies in China: A Look Ahead https://novapharmanews.com/apac/news/asia-pacific-eclinical-solutions-market-report-2025-2030 2026-06-01T05:43:12.559Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Asia Pacific eClinical Solutions Market Report 2025-2030: Key Insights https://novapharmanews.com/uploads/articles/asia-pacific-eclinical-solutions-market-report-2025-2030.webp Asia Pacific eClinical Solutions Market Report 2025-2030: Key Insights https://novapharmanews.com/apac/news/smarter-medical-devices-ecosystem-india-regulatory-updates 2026-06-01T05:43:51.652Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates https://novapharmanews.com/uploads/articles/smarter-medical-devices-ecosystem-india-regulatory-updates.webp Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates https://novapharmanews.com/apac/news/uk-clinical-trials-oncology-impact 2026-06-01T05:44:38.496Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z UK Clinical Trials in Oncology: Actions Driving Impact oncology https://novapharmanews.com/uploads/articles/uk-clinical-trials-oncology-impact.webp UK Clinical Trials in Oncology: Actions Driving Impact https://novapharmanews.com/eu/news/esmo-asia-nadia-harbeck-oncology-advances 2026-06-01T05:44:33.794Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Insights from ESMO Asia: Nadia Harbeck on Oncology Advances oncology https://novapharmanews.com/uploads/articles/esmo-asia-nadia-harbeck-oncology-advances.webp Insights from ESMO Asia: Nadia Harbeck on Oncology Advances https://novapharmanews.com/eu/news/innovent-pfizer-cancer-drug-deal 2026-06-01T05:44:36.954Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal cancer https://novapharmanews.com/uploads/articles/innovent-pfizer-cancer-drug-deal.webp Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal https://novapharmanews.com/eu/news/lenz-therapeutics-vizz-ema-presbyopia 2026-06-01T05:44:46.364Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z LENZ Therapeutics Submits VIZZ® Application to EMA for Presbyopia VIZZ, Presbyopia https://novapharmanews.com/uploads/articles/lenz-therapeutics-vizz-ema-presbyopia.webp LENZ Therapeutics Submits VIZZ® Application to EMA for Presbyopia https://novapharmanews.com/eu/news/arrowhead-pharmaceuticals-positive-clinical-data-eas-congress 2026-06-01T05:43:59.632Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Arrowhead Pharmaceuticals Unveils Positive Clinical Data at EAS Congress cardiometabolic disorders https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-positive-clinical-data-eas-congress.webp Arrowhead Pharmaceuticals Unveils Positive Clinical Data at EAS Congress https://novapharmanews.com/eu/news/chmp-negative-stance-acadia-rett-syndrome-drug 2026-05-31T15:26:48.448Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z CHMP's Negative Stance on Acadia's Rett Syndrome Drug Acadia, Rett syndrome https://novapharmanews.com/uploads/articles/chmp-negative-stance-acadia-rett-syndrome-drug.webp CHMP's Negative Stance on Acadia's Rett Syndrome Drug https://novapharmanews.com/eu/news/cancer-therapy-ost-her2-2026-ema-call 2026-06-01T05:44:34.860Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data OST-HER2, cancer https://novapharmanews.com/uploads/articles/cancer-therapy-ost-her2-2026-ema-call.webp Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data https://novapharmanews.com/eu/news/owkin-astrazeneca-ai-collaboration-drug-research 2026-06-01T05:44:00.573Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Owkin and AstraZeneca Enhance AI Collaboration for Drug Research https://novapharmanews.com/uploads/articles/owkin-astrazeneca-ai-collaboration-drug-research.webp Owkin and AstraZeneca Enhance AI Collaboration for Drug Research https://novapharmanews.com/eu/news/innovent-biologics-shares-surge-pfizer-deal 2026-06-01T05:44:22.175Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Innovent Biologics Shares Surge 10% Following Pfizer Deal https://novapharmanews.com/uploads/articles/innovent-biologics-shares-surge-pfizer-deal.webp Innovent Biologics Shares Surge 10% Following Pfizer Deal https://novapharmanews.com/eu/news/chmp-may-2026-output-shift-european-drug-development 2026-06-01T06:26:30.831Z NovaPharmaNews en-GB 2026-05-30T13:14:56.236Z CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/uploads/articles/chmp-may-2026-drug-approvals.webp CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/us/news/lunai-bioworks-brainstorm-therapeutics-ai-collaboration 2026-06-01T05:24:45.279Z NovaPharmaNews en-US 2026-05-30T13:14:56.236Z Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/lunai-bioworks-brainstorm-therapeutics-ai-collaboration.webp Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy https://novapharmanews.com/us/news/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates 2026-05-31T13:33:11.951Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI and Brain Organoids Combat Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates.webp AI and Brain Organoids Combat Parkinson's and Rare Epilepsy https://novapharmanews.com/us/news/longeveron-stockholder-letter-corporate-strategy-2026-goals 2026-06-01T06:33:09.535Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/uploads/articles/longeveron-stockholder-letter-corporate-strategy-2026-goals.webp Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/us/news/regeneron-fda-approval-neurosensory-gene-therapy 2026-05-31T20:46:01.455Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy gene therapy https://novapharmanews.com/uploads/articles/regeneron-fda-approval-neurosensory-gene-therapy.webp Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy https://novapharmanews.com/us/news/regulatory-actions-may-2026 2026-05-31T21:03:21.357Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/uploads/articles/regulatory-actions-may-2026.webp Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/us/news/life-sciences-dealmaking-momentum-strategic-pressures 2026-05-31T13:41:07.635Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/uploads/articles/life-sciences-dealmaking-momentum-strategic-pressures.webp Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/us/news/pharmtech-regulatory-roundup-may-2026-drug-approvals 2026-06-01T05:29:21.667Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/uploads/articles/pharmtech-regulatory-roundup-may-2026-drug-approvals.webp PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/us/news/fda-commissioner-resignation-drug-approvals 2026-06-01T05:30:59.282Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/uploads/articles/fda-commissioner-resignation-drug-approvals.webp FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/us/news/bizengri-fda-national-priority-rare-bile-duct-cancer 2026-06-01T06:29:45.933Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer Bizengri, rare bile duct cancer https://novapharmanews.com/uploads/articles/bizengri-fda-national-priority-rare-bile-duct-cancer.webp Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer https://novapharmanews.com/us/news/ai-breast-cancer-risk-prediction-tool-fda-approval 2026-06-01T05:43:17.820Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI Breast Cancer Risk Prediction Tool Gains FDA Approval oncology, breast cancer https://novapharmanews.com/uploads/articles/ai-breast-cancer-risk-prediction-tool-fda-approval.webp AI Breast Cancer Risk Prediction Tool Gains FDA Approval https://novapharmanews.com/us/news/vir-biotechnology-stock-board-reshuffle-governance-votes 2026-06-01T02:38:26.311Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/uploads/articles/vir-biotechnology-stock-board-reshuffle-governance-votes.webp Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/us/news/pfizer-innovent-deal-global-drug-development-oncology 2026-06-01T05:44:13.448Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-deal-global-drug-development-oncology.webp Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology https://novapharmanews.com/us/news/big-pharma-ma-spree-march-ipo-drought 2026-05-31T13:33:17.666Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/uploads/articles/big-pharma-ma-spree-march-ipo-drought.webp Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/us/news/editas-medicine-inc-stock-quiet-trading-clinical-trials 2026-06-01T02:38:07.128Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/uploads/articles/editas-medicine-inc-stock-quiet-trading-clinical-trials.webp Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/us/news/big-pharma-biotech-assets-patent-cliff 2026-06-01T02:37:25.991Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/uploads/articles/big-pharma-biotech-assets-patent-cliff.webp Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/us/news/states-confront-medical-chatbots-oversight-fda-inaction 2026-05-31T16:52:57.920Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/uploads/articles/states-confront-medical-chatbots-oversight-fda-inaction.webp States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/us/news/pharma-ma-boom-2026-market-analysis 2026-05-31T20:03:15.617Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/uploads/articles/pharma-ma-boom-2026-market-analysis.webp Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/eu/news/pfizer-innovent-105bn-adc-oncology-partnership 2026-06-01T05:44:25.294Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-105bn-adc-oncology-partnership.webp Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership https://novapharmanews.com/eu/news/imfinzi-approval-bladder-cancer 2026-06-01T06:26:26.136Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer durvalumab, Imfinzi, oncology, non-muscle-invasive bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-approval-bladder-cancer.webp IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer https://novapharmanews.com/eu/news/pfizer-innovent-cancer-drug-alliance 2026-06-01T05:47:27.882Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-cancer-drug-alliance.webp Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance https://novapharmanews.com/eu/news/imfinzi-fda-approval-bladder-cancer 2026-06-01T06:13:07.016Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Imfinzi Receives FDA Approval for Bladder Cancer Treatment Imfinzi, oncology, bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-fda-approval-bladder-cancer.webp Imfinzi Receives FDA Approval for Bladder Cancer Treatment https://novapharmanews.com/eu/news/pfizer-innovent-10-5bn-oncology-deal 2026-06-01T05:44:48.437Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-10-5bn-oncology-deal.webp Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means https://novapharmanews.com/eu/news/esmo-2025-preview-astra-daiichi-gilead 2026-06-01T05:44:44.782Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z ESMO 2025 Preview: Astra and Daiichi vs. Gilead oncology https://novapharmanews.com/uploads/articles/esmo-2025-preview-astra-daiichi-gilead.webp ESMO 2025 Preview: Astra and Daiichi vs. Gilead https://novapharmanews.com/eu/news/prac-meeting-highlights-may-2026 2026-06-01T05:44:49.727Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/uploads/articles/prac-meeting-highlights-may-2026.webp PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/eu/news/2026-cell-therapy-regulatory-landscape 2026-06-01T05:44:24.874Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Navigating the 2026 Cell Therapy Regulatory Landscape cell therapy https://novapharmanews.com/uploads/articles/2026-cell-therapy-regulatory-landscape.webp Navigating the 2026 Cell Therapy Regulatory Landscape https://novapharmanews.com/eu/news/italy-fourth-europe-clinical-research-enrollment 2026-06-01T05:44:13.996Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/uploads/articles/italy-fourth-europe-clinical-research-enrollment.webp Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/eu/news/critical-medicines-act-council-parliament-deal 2026-06-01T05:43:54.279Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/uploads/articles/critical-medicines-act-council-parliament-deal.webp Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/eu/news/merz-therapeutics-kvvit-inbrija-agreement 2026-05-31T18:23:51.744Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® INBRIJA, levodopa https://novapharmanews.com/uploads/articles/merz-therapeutics-kvvit-inbrija-agreement.webp Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® https://novapharmanews.com/apac/news/clinical-trials-market-oncology-2034 2026-06-01T06:10:50.580Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Clinical Trials Market in Oncology: Size and Growth Insights for 2034 oncology https://novapharmanews.com/uploads/articles/clinical-trials-market-oncology-2034.webp Clinical Trials Market in Oncology: Size and Growth Insights for 2034 https://novapharmanews.com/apac/news/premia-lind-ai-clinical-trial-screening-asia-pacific 2026-06-01T05:43:31.326Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/uploads/articles/premia-lind-ai-clinical-trial-screening-asia-pacific.webp PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-april-20-2026 2026-06-01T05:43:56.425Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-april-20-2026.webp Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/apac/news/cell-gene-therapy-approvals-china-regulatory-updates 2026-06-01T05:43:57.649Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Cell and Gene Therapy Approvals in China: Latest Regulatory Updates gene therapy https://novapharmanews.com/uploads/articles/cell-gene-therapy-approvals-china-regulatory-updates.webp Cell and Gene Therapy Approvals in China: Latest Regulatory Updates https://novapharmanews.com/apac/news/innovent-biologics-pfizer-10-5b-oncology-partnership 2026-06-01T05:44:29.545Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Innovent Biologics and Pfizer: A $10.5B Oncology Partnership oncology, cancer https://novapharmanews.com/uploads/articles/innovent-biologics-pfizer-10-5b-oncology-partnership.webp Innovent Biologics and Pfizer: A $10.5B Oncology Partnership https://novapharmanews.com/apac/news/onconic-therapeutics-jakubo-phase-3-clinical-trials-china 2026-06-01T05:44:03.292Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China https://novapharmanews.com/uploads/articles/onconic-therapeutics-jakubo-phase-3-clinical-trials-china.webp Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China